Taylor Sandison, MD, MPH

Poster(s):

• 637 - Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

• 1174 - Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations

• 1284 - Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

• 1286 - Pharmacokinetics, Excretion, and Mass Balance of [¹⁴C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults